Pharmidex has joined the Good Clinical Practice (GCP) Network
February 17, 2026
We’re proud to announce that
Pharmidex has joined the
Good Clinical Practice (GCP) Network, a global collaboration advancing ICH-GCP excellence in clinical research.
For us, quality and data integrity are not box-ticking exercises, they are fundamental to credible science and responsible drug development.
From pre-clinical research through to clinical delivery, we are committed to:
• Regulatory rigour
• Ethical conduct
• Participant protection
• Scientifically robust data
Joining the GCP Network further strengthens that commitment.
We look forward to contributing to a global community dedicated to raising the bar across clinical research.
Pharmidex now offers integrated in vivo CAR-T study support , combining robust in-life pharmacology with advanced f low cytometry –based cellular analysis. We support early-stage CAR-T and cell therapy programmes with translational data on efficacy, expansion, persistence and phenotype delivered through a single collaborative CRO partner. Let’s talk. 🌐 www.pharmidex.com
Pharmidex is pleased to share that Janette Dalay Robertson will be attending the Founders Growth Community Meeting and Networking x Innovate Cambridge event at The Glasshouse, Cambridge. Janette will be available to meet between 12:00–15:30 and looks forward to connecting with fellow attendees to explore new alliances in pre-clinical and clinical drug development. If you’re attending, let’s connect.
We’re excited to announce that Pharmidex has expanded its analytical capabilities with the addition of the xMAP INTELLIFLEX™ system, a powerful, high-performance platform for multiplex biomarker analysis. This advanced technology enables the simultaneous measurement of multiple analytes from minimal sample volumes, delivering exceptional sensitivity, accuracy and reproducibility. It is ideally suited for complex biological matrices and supports a wide range of applications, from biomarker discovery to translational and preclinical studies. Our INTELLIFLEX™ supports dual reporter channels to collect more data per sample. 🔬 What this means for our partners and the wider scientific community: • Faster, data-rich insights from fewer samples • Enhanced assay flexibility and scalability • Improved data quality to support confident decision-making • Greater efficiency across drug discovery and development programmes This investment strengthens Pharmidex’s commitment to scientific excellence, allowing us to deliver even more robust, innovative and reliable services to pharma, biotech, CROs and academic collaborators. We look forward to putting this new capability to work in support of better science and better medicines.
